Psychiatry, Antipsychotic, Internal medicine, Schizophrenia and Bipolar disorder are his primary areas of study. His studies in Psychiatry integrate themes in fields like Young adult and Randomized controlled trial. His Antipsychotic research integrates issues from Tolerability, Adverse effect, Pharmacology, Intensive care medicine and Weight gain.
His biological study spans a wide range of topics, including Placebo, Clozapine and Atypical antipsychotic. His Schizophrenia research is multidisciplinary, incorporating perspectives in Abdominal obesity, Quality of life, Polypharmacy, Mental illness and Major depressive disorder. His Bipolar disorder research is multidisciplinary, incorporating elements of Psychological intervention and Mood.
His primary areas of study are Psychiatry, Internal medicine, Antipsychotic, Schizophrenia and Meta-analysis. He works mostly in the field of Psychiatry, limiting it down to topics relating to MEDLINE and, in certain cases, Intensive care medicine, as a part of the same area of interest. While the research belongs to areas of Internal medicine, he spends his time largely on the problem of Olanzapine, intersecting his research to questions surrounding Quetiapine and Risperidone.
His Antipsychotic research is multidisciplinary, relying on both Discontinuation, Adverse effect, Polypharmacy, Weight gain and Pediatrics. His study on Clozapine, Positive and Negative Syndrome Scale and Schizoaffective disorder is often connected to In patient as part of broader study in Schizophrenia. His work deals with themes such as Odds ratio and Relative risk, which intersect with Meta-analysis.
His primary scientific interests are in Internal medicine, Antipsychotic, Schizophrenia, Psychiatry and Adverse effect. Christoph U. Correll has researched Internal medicine in several fields, including Gastroenterology and Olanzapine. Christoph U. Correll interconnects Neuropsychopharmacology, Incidence, MEDLINE, Rating scale and Aripiprazole in the investigation of issues within Antipsychotic.
His research in Schizophrenia intersects with topics in Psychosis, Randomized controlled trial, Cognition and Clinical psychology. His study in Schizophrenia and Anxiety falls within the category of Psychiatry. Christoph U. Correll works mostly in the field of Adverse effect, limiting it down to concerns involving Placebo and, occasionally, Exacerbation.
His scientific interests lie mostly in Antipsychotic, Internal medicine, MEDLINE, Schizophrenia and Psychiatry. The Antipsychotic study combines topics in areas such as Clinical trial, Hazard ratio, Major depressive disorder, Medical prescription and Pediatrics. His studies in Internal medicine integrate themes in fields like Prediabetes and Ziprasidone.
His MEDLINE research incorporates elements of Dosing and Intensive care medicine. His Schizophrenia research integrates issues from Adverse effect, Psychosis and Randomized controlled trial. His research integrates issues of Treatment outcome and Emotional expression in his study of Psychiatry.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Physical illness in patients with severe mental disorders.I. Prevalence, impact of medications and disparities in health care
Marc De Hert;Christoph U. Correll;Julio Bobes;Marcelo Cetkovich-Bakmas.
World Psychiatry (2011)
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
Christoph U. Correll;Peter Manu;Vladimir Olshanskiy;Barbara Napolitano.
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
Marc De Hert;Johan Detraux;Ruud van Winkel;Weiping Yu.
Nature Reviews Endocrinology (2012)
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.
Christoph U. Correll;Stefan Leucht;John M. Kane.
American Journal of Psychiatry (2004)
Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level
Marc De Hert;Dan Cohen;Julio Bobes;Marcelo Cetkovich-Bakmas.
World Psychiatry (2011)
Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.
Christoph U. Correll;Marco Solmi;Nicola Veronese;Beatrice Bortolato.
World Psychiatry (2017)
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.
Stefan Leucht;Thomas R.E. Barnes;Werner Kissling;Rolf R. Engel.
American Journal of Psychiatry (2003)
Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
Christoph U. Correll;Johan Detraux;Jan De Lepeleire;Marc De Hert.
World Psychiatry (2015)
Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program
John M. Kane;Delbert G. Robinson;Nina R. Schooler;Kim T. Mueser.
American Journal of Psychiatry (2016)
Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis
Davy Vancampfort;Brendon Stubbs;Alex J Mitchell;Marc De Hert.
World Psychiatry (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: